Roche's Cotellic Gets EU CHMP Endorsement
This article was originally published in Scrip
Following a Swiss lead, the EU's CHMP has granted a positive opinion on approval of Roche (Genentech)/ Exelixis's selective MEK inhibitor cobimetinib (as Cotellic) for use in combination with Roche's BRAF inhibitor Zelboraf (vemurafenib), for the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma.
You may also be interested in...
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
Phase II results look good for one of the first-in-class product’s potential indications, C3 glomerulopathy. The product was highlighted late last year as an up-and-coming pipeline asset.